Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Phase 1 Recruiting
36 enrolled
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
Phase 1 Recruiting
35 enrolled
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Phase 1 Recruiting
24 enrolled
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Phase 1 Recruiting
83 enrolled
Study of BM230 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
123 enrolled
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Phase 1 Recruiting
60 enrolled
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Phase 1 Recruiting
30 enrolled
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Phase 1 Recruiting
24 enrolled
SB17170 Phase 1 Clinical Trial in Solid Tumors
Phase 1 Recruiting
50 enrolled
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Phase 1 Recruiting
95 enrolled
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1 Recruiting
128 enrolled
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
300 enrolled
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
21 enrolled
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Phase 1 Recruiting
200 enrolled
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase 1 Recruiting
105 enrolled
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
216 enrolled
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Phase 1 Recruiting
25 enrolled
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
51 enrolled
Study of STP938 in Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
22 enrolled
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
12 enrolled
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Phase 1 Recruiting
219 enrolled
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
30 enrolled
Oral Paclitaxel for Patients with Advanced Solid Tumors
Phase 1 Recruiting
70 enrolled
A Study of CBP-1018 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
170 enrolled
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
85 enrolled
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Phase 1 Recruiting
44 enrolled
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
54 enrolled
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Phase 1 Recruiting
12 enrolled
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
44 enrolled
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Phase 1 Recruiting
15 enrolled
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
Phase 1 Recruiting
9 enrolled
A Study of AK131 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Phase 1 Recruiting
157 enrolled
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Phase 1 Recruiting
24 enrolled